Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Tirzepatide (Mounjaro), a dual GLP-1/GIP receptor agonist, received UK approval for type 2 diabetes and is under evaluation for obesity treatment
Currently, the FDA has approved three GLP-1 RAs for obesity treatment: liraglutide, semaglutide and tirzepatide
Fiber-rich options that support digestion Soluble fiber helps regulate digestive transit and can improve the balance of gut bacteria over time
Clinical Medicine Insights: Therapeutics, 12, 110
Expert Insights: Dr
US$ 24.33
US$ 21.09
US$ 27.39
US$ 28.55
US$ 26.90
US$ 28.15
